inecalcitol (TX-522) / Hybrigenics - LARVOL DELTA

Faecalibacterium prausnitzii enhances intestinal IgA response by host-microbe derived inecalcitol in colitis. (PubMed, BMC Med) - "F. prausnitzii effectively alleviated colonic inflammation and modulated dysbiosis via enhancing colonic IgA response, thus showing promise as a UC treatment."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Transplantation • Ulcerative Colitis • AICDA

Synergistic Effects of Inecalcitol With Imatinib and Dasatinib on Chronic Myeloid Leukemia Cell Lines. (PubMed, Anticancer Res) - "The study suggests that the synergistic effects of inecalcitol with imatinib on cell killing are more drastic in some cells than others. These varying effects may be due to differences in cell metabolism."

Journal • Preclinical • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology

Biological evaluation of combinations of tyrosine kinase inhibitors with Inecalcitol as novel treatments for human chronic myeloid leukemia. (PubMed, Saudi Pharm J) - "Furthermore, the combination treatments showed synergistic interaction between the antileukemic drugs and Inecalcitol, with combination indices (CI) < 1. The study demonstrated that the human chronic myeloid leukemia K-562 cells were subjected to a synergistic growth inhibitory impact when antileukemic drugs (Imatinib or Dasatinib) were combined with Inecalcitol, therefore, it is recommended that these combinations be viewed as promising novel antileukemic medications and used in place of individual medications with lower dosages and negligible side effects in the treatment of CML."

Journal • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology

The Combination of the CDK4/6 Inhibitor, Palbociclib, With the Vitamin D Analog, Inecalcitol, Has Potent In Vitro and In Vivo Anticancer Effects in Hormone-Sensitive Breast Cancer, But Has a More Limited Effect in Triple-Negative Breast Cancer. (PubMed, Front Endocrinol (Lausanne)) - "Furthermore, in vivo validation in a MCF7 cell line-derived xenograft mouse model decreased tumor growth and cell cycle progression after combination therapy, but not in a TNBC BT20 cell line-derived xenograft model. In conclusion, we show that addition of a potent vitamin D analog to selective CDK4/6 inhibitor treatment results in increased antiproliferative effects in ER BC both in vitro and in vivo."

Journal • Preclinical • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CDK2 • EIF4EBP1

Inecalcitol respectively induces or increases CD38 expression at the surface of CD38- or CD38+ AML cell lines representative of all 9 FAB subtypes except M6 (AACR 2018) - "In conclusion, after exposure to inecalcitol, CD38 appeared at the surface of CD38- AML cell lines and the density of CD38 increased at the surface of CD38+ AML cell lines, altogether representative of all 9 FAB classification subtypes M0 to M7, except M6 (erythrocytic) which represents 5% of all AML cases. These results suggest that treatment by inecalcitol may render 95% of AML patients sensitive to highly sensitive to anti-CD38 immunotherapy such as daratumumab."

IO Biomarker • Acute Myelogenous Leukemia

Hybrigenics : green light for two European patents protecting new oral formulations of inecacitol (4 Traders) - "Hybrigenics...announces it has received from the European Patent Office the official notification of its intent to grant, after an accelerated examination procedure, two patents on new pharmaceutical formulations allowing a better absorption of inecalcitol. One patent covers innovative tablets, an unusual formulation for a vitamin D receptor agonist like inecalcitol. The other patent protects a second generation of soft gelatin capsules with a higher concentration of inecalcitol"

Patent • Psoriasis